Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market artrix2022-03-10T23:01:42-08:00
Aadi Bioscience Announces FDA Approval FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)artrix2022-03-10T22:59:36-08:00